江蘇荃信生物醫藥股份有限公司（02509）于2026年1月13日发布翌日披露报表，公告显示公司当日于香港联交所回购2.84万股H股。回购价每股为22.40港元，涉资总额约63.62万港元，回购股份占前一交易日已发行股本的0.0126%。回购后，公司于2026年1月13日收市时的已发行股本（不含库藏股）变更为225,387,800股，库藏股数量增至1,683,800股，已发行股份总数则保持227,071,600股不变。
回购授权于2025年6月20日获通过，授权最多回购22,207,160股。截至目前，累计在联交所购回1,683,800股，占授权通过当日公司已发行股本的0.7582%。公告同时披露，公司于回购后30天内不会发行新股或出售、转让库藏股份（法定豁免情况除外），现行暂止期将持续至2026年2月12日。
公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律条文。公告由董事会秘書和联席公司秘書胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.